References
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M,
Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide:
Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer
2015; 136: 359–86.
- National Cancer Center Cancer Control Information in Japan.
https://ganjoho.jp/reg_stat/statistics/stat/cancer/17_cervix_uteri.html
- Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human
papillomavirus and cervical cancer. Lancet 2013; 382: 889–99.
- Small W Jr, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM,
Jhingran A, Kitchener HC, Mileshkin LR, Viswanathan AN, Gaffney DK.
Cervical cancer: A global health crisis. Cancer 2017; 123: 2404–12.
- Sakamoto J, Kamiura S, Okayama K, Okodo M, Shibata T, Osaka Y, Fujita
S, Takata E, Takagi H, Takakura M, Sasagawa T. Single type infection
of human papillomavirus as a cause for high-grade cervical
intraepithelial neoplasia and invasive cancer in Japan. Papillomavirus
Res 2018; 6: 46–51.
- Onuki M, Yamamoto K, Yahata H, Kanao H, Yokota H, Kato H, Shimamoto K,
Takehara K, Kamiura S, Tsuda N, Takei Y, Shigeta S, Matsumura N,
Yoshida H, Motohara T, Watari H, Nakamura K, Ueda A, Tasaka N,
Ishikawa M, Hirashima Y, Kudaka W, Taguchi A, Iwata T, Takahashi F,
Kukimoto I, Yoshikawa H, Yaegashi N, Matsumoto K; MINT Study Group.
Human papillomavirus vaccine effectiveness by age at first vaccination
among Japanese women. Cancer Sci 2022; 113: 1428–34.
- WHO. A cervical cancer-free future: First-ever global commitment to
eliminate a cancer. 17 November 2020
- Palmer T, Wallace L, Pollock KG, Cuschieri K, Robertson C, Kavanagh K,
Cruickshank M. Prevalence of cervical disease at age 20 after
immunisation with bivalent HPV vaccine at age 12-13 in Scotland:
Retrospective population study. BMJ 2019; 365: l1161.
https://doi.org/10.1136/bmj.l1161
- Patel C, Brotherton JM, Pillsbury A, Jayasinghe S, Donovan B,
Macartney K, Marshall H. The impact of 10 years of human
papillomavirus (HPV) vaccination in Australia: What additional disease
burden will a nonavalent vaccine prevent? Euro Surveill 2018; 23:
pii=1700737. https://doi.org/10.2807/15607917
- Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F, Sundström K,
Dillner J, Sparén P. HPV vaccination and the risk of invasive cervical
cancer. N Engl J Med 2020; 383: 1340–8.
https://doi.org/10.1056/NEJMoa1917338
- Falcaro M, Castañon A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J,
Elliss-Brookes L, Sasieni P. The effects of the national HPV
vaccination programme in England, UK, on cervical cancer and grade 3
cervical intraepithelial neoplasia incidence: A register-based
observational study. Lancet 2021; 398: 2084–92.https://doi.org/10.1016/S0140-6736(21)02178-4
- Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer H, Beddows S,
Brisson J, Brotherton JM, Cummings T, Donovan B, Fairley CK, Flagg EW,
Johnson AM, Kahn JA, Kavanagh K, Kjaer SK, Kliewer EV,
Lemieux-Mellouki P, Markowitz L, Mboup A, Mesher D, Niccolai L,
Oliphant J, Pollock KG, Soldan K, Sonnenberg P, Tabrizi SN, Tanton C,
Brisson M. Population-level impact and herd effects following human
papillomavirus vaccination programs: A systematic review and
meta-analysis. Lancet Infect Dis 2015; 15: 565–80.
https://doi.org/10.1016/S1473-3099(14)71073-4
- Donken R, King AJ, Bogaards JA, Woestenberg PJ, Meijer CJLM, de Melker
HE. High effectiveness of the bivalent human papillomavirus (HPV)
vaccine against incident and persistent HPV infections up to 6 years
after vaccination in young Dutch women. J Infect Dis 2018; 217:
1579–89. https://doi.org/10.1093/infdis/jiy067
- Gargano JW, McClung N, Lewis RM, Park IU, Whitney E, Castilho JL,
Pemmaraju M, Niccolai LM, Brackney M, DeBess E, Ehlers S, Bennett NM,
Scahill M, Cleveland AA, Querec TD, Unger ER, Markowitz LE; HPV-IMPACT
Working Group. HPV type-specific trends in cervical precancers in the
United States, 2008 to 2016. Int J Cancer 2023; 152: 137–50.
https://doi.org/10.1002/ijc.34231
- Covert C, Ding L, Brown D, Franco EL, Bernstein DI, Kahn JA. Evidence
for cross-protection but not type-replacement over the 11 years after
human papillomavirus vaccine introduction. Hum Vaccin Immunother 2019;
15: 1962–9. https://doi.org/10.1080/21645515.2018.1564438
- Saccucci M, Franco EL, Ding L, Bernstein DI, Brown D, Kahn JA.
Non-vaccine-type human papillomavirus prevalence after vaccine
introduction: No evidence for type replacement but evidence for
cross-protection. Sex Transm Dis 2018; 45: 260–5.
https://doi.org/10.1097/OLQ.0000000000000731
- Simms KT, Hanley SJB, Smith MA, Keane A, Canfell K. Impact of HPV
vaccine hesitancy on cervical cancer in Japan: A modelling study.
Lancet Public Health 2020; 5: e223–34. https://doi.org/10.1016/S2468
2667(20)30010-4
- Information of HPV-vaccine program from April 2022; Ministry of
Health, Labour and Welfare, Japan.
https://www.mhlw.go.jp/content/10906000/000911549.pdf
- Karube A, Saito F, Nakamura E, Shitara A, Ono N, Konno M, Tamura D,
Nagao D. Reduction in HPV 16/18 prevalence among young women following
HPV vaccine introduction in a highly vaccinated district, Japan,
2008-2017. J Rural Med 2019; 14: 48–57.
https://doi.org/10.2185/jrm.2986
- Ikeda S, Ueda Y, Hara M, Yagi A, Kitamura T, Kitamura Y, Konishi H,
Kakizoe T, Sekine M, Enomoto T, Sobue T. Human papillomavirus vaccine
to prevent cervical intraepithelial neoplasia in Japan: A nationwide
case-control study. Cancer Sci 2021; 112: 839–46.
https://doi.org/10.1111/cas.14682
- Kudo R, Yamaguchi M, Sekine M, Adachi S, Ueda Y, Miyagi E, Hara M,
Hanley SJB, Enomoto T. Bivalent human papillomavirus vaccine
effectiveness in a Japanese population: High vaccine-type-specific
effectiveness and evidence of cross-protection. J Infect Dis 2019;
219: 382–90. https://doi.org/10.1093/infdis/jiy516
- Matsumoto K, Yaegashi N, Iwata T, Yamamoto K, Aoki Y, Okadome M,
Ushijima K, Kamiura S, Takehara K, Horie K, Tasaka N, Sonoda K, Takei
Y, Aoki Y, Konnai K. Reduction in HPV16/18 prevalence among young
women with high-grade cervical lesions following the Japanese HPV
vaccination program. Cancer Sci 2019; 110: 3811–20.
https://doi.org/10.1111/cas.14212
- Sasagawa T, Maehama T, Ideta K, Irie T; Fujiko Itoh J-HERS Study
Group. Population-based study for human papillomavirus (HPV) infection
in young women in Japan: A multicenter study by the Japanese human
papillomavirus disease education research survey group (J-HERS). J Med
Virol 2016; 88: 324–35.
The English in this document has been checked by at least two
professional editors, both native speakers of English. For a
certificate, please see:http://www.textcheck.com/certificate/1v9Kxo